Search - tctmd.com

Displaying 581 - 600 of 1262

Sort: Relevancy | Date

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

October 14, 2020

Delays, Deaths, and More Cardiogenic Shock Among ACS Patients With COVID-19

News Conference News TCT 2020

Delays, Deaths, and More Cardiogenic Shock Among ACS Patients With COVID-19

October 14, 2020

STEMI Door-to-Balloon Times Haven’t Suffered During COVID-19: NACMI

News Conference News TCT 2020

STEMI Door-to-Balloon Times Haven’t Suffered During COVID-19: NACMI

October 14, 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

News Conference News

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

September 10, 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

September 04, 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

In Long-term, Real-world Data CABG Bests PCI for Diabetic Patients With MVD

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

August 31, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

Trimetazidine Safe but Not Protective Long-term After PCI

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

August 30, 2020

News Conference News ESC 2020

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

August 30, 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.